Literature DB >> 25169048

Individual differences in novelty-seeking behavior in spontaneously hypertensive rats: Enhanced sensitivity to the reinforcing effect of methylphenidate in the high novelty-preferring subpopulation.

Ike dela Peña1, Edson Luck Gonzales2, June Bryan de la Peña1, Bung-Nyun Kim3, Doug Hyun Han4, Chan Young Shin2, Jae Hoon Cheong5.   

Abstract

BACKGROUND: High novelty seeking has been assumed to predict vulnerability to use addictive drugs. Notably, it is also a symptom associated with attention-deficit/hyperactivity disorder (ADHD). The aim of this study was to identify whether spontaneously hypertensive rats (SHRs), putative animal models of ADHD, display individual differences in novelty-seeking behavior, and whether high novelty-seeking SHRs show enhanced sensitivity to the reinforcing effect of methylphenidate, the most commonly prescribed stimulant ADHD medication.
METHODS: First, we established that SHRs show higher levels of novelty-seeking behavior than their normotensive control strain, Wistar Kyoto (WKY) rats. Novelty seeking was measured in two tests: open field test in a novel test arena, and novel object preference tests. Thereafter, SHRs were classified into high responders (HR) or low responders (LR), high novelty-preferring (HNP) or low novelty-preferring (LNP) rats, based on individual scores in the two behavioral assays. Methylphenidate self-administration was assessed thereafter.
RESULTS: SHRs showed higher levels of novelty-seeking behavior than WKY rats. HR/LR and HNP/LNP subgroups were identified. HR and LR rats showed comparable rates of methylphenidate self-administration. However, HNP SHRs worked more for methylphenidate infusions than their LNP counterparts.
CONCLUSIONS: We showed some evidence on inter-individual variations in novelty seeking in SHRs. Importantly, we demonstrated enhanced sensitivity of HNP SHRs to the reinforcing effect of methylphenidate, indicating a "drug-vulnerable" SHR subpopulation. These findings are important as they may provide basis for a potential screening tool to identify a subset of ADHD patients (i.e. high novelty seekers) who may be at risk for misusing/abusing methylphenidate.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ADHD; Addiction; Methylphenidate; Novelty-seeking; SHR

Mesh:

Substances:

Year:  2014        PMID: 25169048     DOI: 10.1016/j.jneumeth.2014.08.019

Source DB:  PubMed          Journal:  J Neurosci Methods        ISSN: 0165-0270            Impact factor:   2.390


  5 in total

1.  Adolescent D-amphetamine treatment in a rodent model of ADHD: Pro-cognitive effects in adolescence without an impact on cocaine cue reactivity in adulthood.

Authors:  Chloe J Jordan; Danielle M Taylor; Linda P Dwoskin; Kathleen M Kantak
Journal:  Behav Brain Res       Date:  2015-10-20       Impact factor: 3.332

2.  Treatment of GABA from Fermented Rice Germ Ameliorates Caffeine-Induced Sleep Disturbance in Mice.

Authors:  Darine Froy N Mabunga; Edson Luck T Gonzales; Hee Jin Kim; Se Young Choung
Journal:  Biomol Ther (Seoul)       Date:  2015-05-01       Impact factor: 4.634

Review 3.  Influence of the Novelty-Seeking Endophenotype on the Rewarding Effects of Psychostimulant Drugs in Animal Models.

Authors:  M Carmen Arenas; María A Aguilar; Sandra Montagud-Romero; Ana Mateos-García; Concepción I Navarro-Francés; José Miñarro; Marta Rodríguez-Arias
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

4.  Early postnatal allopregnanolone levels alteration and adult behavioral disruption in rats: Implication for drug abuse.

Authors:  Iris Bartolomé; Anna Llidó; Sònia Darbra; Marc Pallarès
Journal:  Neurobiol Stress       Date:  2019-12-27

5.  Chronic administration of pharmacological doses of angiotensin 1-7 and iodoangiotensin 1-7 has minimal effects on blood pressure, heart rate, and cognitive function of spontaneously hypertensive rats.

Authors:  Filipe F Stoyell-Conti; Alesa Chabbra; Joseph Puthentharayil; Katya Rigatto; Robert C Speth
Journal:  Physiol Rep       Date:  2021-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.